Outlook for Biopharma M&A Remains Bullish into 2019

At the start of the year, EY projected that President Donald Trump’s tax overhaul, growing competition among drug developers, and new sources of capital would drive this year's merger-and-acquisition (M&A) activity well past last year’s $200 billion annual volume of deals .All three are occurring, leading EY’s global biotechnology leader to stay bullish about the prospects for M&A deals during the second half of 2018 and into 2019.“We remain of the view that